"Education of patients (advocates) on R&D: European Patients’ Academy EUPATI", presented by Jan Geissler at the Careum Congress on 18 March 2014 in Basel
EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...EUPATI
This document discusses increasing patient involvement in medical research and development. It notes that the medical landscape is transforming rapidly through innovations like personalized medicine and biomarkers. While this benefits patients, it also means smaller trial populations and a need for more post-marketing data. The document advocates for increasing patient involvement in areas like clinical trial design, setting research priorities, measuring quality of life, and pharmaceutical policy. It highlights the European Patients' Academy (EUPATI) project, which aims to empower patients through education on medical research and development processes in order to facilitate greater patient engagement.
EUPATI 2013 Conference: Building Knowledge & Competences for Patients’ Involv...EUPATI
EUPATI 2013 Conference: Building Knowledge & Competences for Patients’ Involvement in Medicines R&D, “Bring to life with EUPATI examples”, by Niels Westergaard, PhD, DSc Biopeople, University of Copenhagen, Denmark
EUPATI 2013 Conference: Patient involvement in medicines R&D: Bringing to li...EUPATI
"Patient involvement in medicines R&D: Bringing to life with EUPATI", presented by Jan Geissler, EUPATI Director, at the EUPATI 2013 Conference on 19 April 2013
European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 ...EUPATI
European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 June 2013, presented by Jan Geissler (@jangeissler), Director EUPATI (@EUPATIents) at the IMI's "Patient Focus" meeting, convening patient leaders from across Europe
The document summarizes the European Patients' Academy on Therapeutic Innovation (EUPATI) project. EUPATI aims to (1) develop and disseminate education on medicines research and development to patients and the public, (2) build competency among patient advocates, and (3) create a public library on patient information. By empowering patients, EUPATI seeks to facilitate greater patient involvement in research and development to support various stakeholders. Running from 2012 to 2017, EUPATI's consortium of 29 members is funded by the Innovative Medicines Initiative to develop objective and credible educational resources.
Presentation in the framework of the International Conference "10th anniversary of the Spanish Network of Health Technology Assessment Agencies. Towads patient and public engagement in HTA" Zaragoza 27-28 April 2017
Presentation in the framework of the International Conference "10th anniversary of the Spanish Network of Health Technology Assessment Agencies. Towads patient and public engagement in HTA" Zaragoza 27-28 April 2017
EUPATI Status Update at EMA PCWP Meeting, 26 Nov 2015jangeissler
Overview and Status Quo of the European Patients Academy (EUPATI) project, presented by EUPATI Director Jan Geissler at the EMA Patient and Consumer Working Party (PCWP) meeting in London on 26 Nov 2015
EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...EUPATI
This document discusses increasing patient involvement in medical research and development. It notes that the medical landscape is transforming rapidly through innovations like personalized medicine and biomarkers. While this benefits patients, it also means smaller trial populations and a need for more post-marketing data. The document advocates for increasing patient involvement in areas like clinical trial design, setting research priorities, measuring quality of life, and pharmaceutical policy. It highlights the European Patients' Academy (EUPATI) project, which aims to empower patients through education on medical research and development processes in order to facilitate greater patient engagement.
EUPATI 2013 Conference: Building Knowledge & Competences for Patients’ Involv...EUPATI
EUPATI 2013 Conference: Building Knowledge & Competences for Patients’ Involvement in Medicines R&D, “Bring to life with EUPATI examples”, by Niels Westergaard, PhD, DSc Biopeople, University of Copenhagen, Denmark
EUPATI 2013 Conference: Patient involvement in medicines R&D: Bringing to li...EUPATI
"Patient involvement in medicines R&D: Bringing to life with EUPATI", presented by Jan Geissler, EUPATI Director, at the EUPATI 2013 Conference on 19 April 2013
European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 ...EUPATI
European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 June 2013, presented by Jan Geissler (@jangeissler), Director EUPATI (@EUPATIents) at the IMI's "Patient Focus" meeting, convening patient leaders from across Europe
The document summarizes the European Patients' Academy on Therapeutic Innovation (EUPATI) project. EUPATI aims to (1) develop and disseminate education on medicines research and development to patients and the public, (2) build competency among patient advocates, and (3) create a public library on patient information. By empowering patients, EUPATI seeks to facilitate greater patient involvement in research and development to support various stakeholders. Running from 2012 to 2017, EUPATI's consortium of 29 members is funded by the Innovative Medicines Initiative to develop objective and credible educational resources.
Presentation in the framework of the International Conference "10th anniversary of the Spanish Network of Health Technology Assessment Agencies. Towads patient and public engagement in HTA" Zaragoza 27-28 April 2017
Presentation in the framework of the International Conference "10th anniversary of the Spanish Network of Health Technology Assessment Agencies. Towads patient and public engagement in HTA" Zaragoza 27-28 April 2017
EUPATI Status Update at EMA PCWP Meeting, 26 Nov 2015jangeissler
Overview and Status Quo of the European Patients Academy (EUPATI) project, presented by EUPATI Director Jan Geissler at the EMA Patient and Consumer Working Party (PCWP) meeting in London on 26 Nov 2015
This document summarizes an organization called IPPOSI that trains patient experts on clinical research, health technology assessment, and eHealth. It discusses IPPOSI's members from science and industry backgrounds. It also describes EUPATI, a project that develops patient education on medicines research and development. EUPATI has trained over 100 patient experts and created educational materials available to over 12,000 patient advocates and 100,000 members of the public interested in health topics. The goal is to facilitate greater patient involvement in research by building competencies among patients.
EUPATI patient expert training course and its relevance for patient involvementEUPATI
The document discusses the EUPATI Patient Expert Training Course. It aims to educate and empower patients to be actively involved in all stages of medicine research and development from drug discovery through regulatory approval. The course includes 150-175 hours of online learning over 6 modules, along with two in-person meetings. It covers topics like clinical trials, ethics, regulations, health technology assessments, and more. The goal is to train independent and knowledgeable patient advocates who can partner with academics, industry, and regulators. Over 300 patients applied for the first class of 50-50 trainees, showing high interest. The course materials were developed by experts from different stakeholders and underwent extensive review.
Future Health Summit - Dr Derick Mitchell - May 26th 2016ipposi
This document discusses patient involvement in health research. It describes how patients can play key roles across various aspects of research including as public advisors, reviewers, co-researchers, and driving forces. It also outlines training programs for patients, such as those developed by IPPOSI and EUPATI, and how patients can be educated on clinical research, health technology assessment, and other areas. The goal is for patients to have objective knowledge about medical research and development processes to facilitate greater collaboration between patients and researchers.
Presentation in the framework of the International Conference "10th anniversary of the Spanish Network of Health Technology Assessment Agencies. Towads patient and public engagement in HTA" Zaragoza 27-28 April 2017
Presentation in the framework of the International Conference "10th anniversary of the Spanish Network of Health Technology Assessment Agencies. Towads patient and public engagement in HTA" Zaragoza 27-28 April 2017
This document summarizes the discussion from Break-Out Group 1 at the EUPATI 2015 Workshop regarding implementing EUPATI at the national level. Some key benefits of establishing a national EUPATI partner (ENP) include having a central point of contact for health policy questions, connecting diverse stakeholders, and facilitating multi-sectoral cooperation. National partners could include patient organizations, academics, regulatory authorities, healthcare professionals, and pharmaceutical companies. Strategic priorities for ENPs include disseminating EUPATI training and strengthening partnerships. Success would involve raising awareness, securing institutional support and sustainable funding, and becoming a go-to resource. ENPs should focus on building relationships, learning from more established programs, and leveraging partnerships
Introduction to the workshop and EUPATI updateEUPATI
The European Patients' Academy (EUPATI) project aims to educate patients and the public about medical research and development. It provides training to help patients become experts who can actively partner with researchers. The project is led by patients and involves various stakeholders. It has made progress in developing educational materials in multiple languages and establishing national networks. The first training course for patient experts recently began. EUPATI seeks to build understanding and empower patients to more actively engage in research.
The document discusses setting up a National Learning Team (NLT) to establish a European Patients' Academy (ENP) in their country to implement the EUPATI program before the end of 2015. Key points discussed include finding champions in patient organizations, academia, and industry; creating effective partnerships between these stakeholders; developing strategic links and growing networks; and emphasizing the benefits EUPATI can provide like training opportunities and access to resources to promote patient public involvement.
Reaching a public audience on medicines development: Anna ZawadaNowgen
"Reaching a public audience on medicines development", presented by Anna Zawada, Agency for Health Technology Assessment at EUPATI 2014 Workshop on 2 April 2014 in Warsaw
What were the success factors in this morning good practices examples, what a...Nowgen
"What were the success factors in this morning good practices examples", Results from Workgroup 2 presented by at EUPATI 2014 Workshop on 2 April 2014 in Warsaw
This document discusses patient involvement in science, industry, and research. It describes how the Irish Platform for Patient Organizations, Science and Industry (IPPOSI) brings together patient experts and organizations to encourage dialogue and influence decision making. IPPOSI members include patient experts in science and industry. The document also discusses the European Patients' Academy on Therapeutic Innovation (EUPATI) which provides training for patient experts through courses and educational materials. EUPATI aims to facilitate greater patient involvement in research and development.
A very important result from the EUPATI project was the development, broad consultation and final release of guidances on the best approach to interaction of patients with pharmaceutical industry-led medicines R&D, regulatory authorities, ethics committees and HTA agencies. This webinar focuses on the Patient Involvement in Industry-led R&D guidance document
How to raise interest in medicines development: Results from Workgroup 1Nowgen
The document reports on a workshop discussing strategies to raise public interest in medicines development. Participants were divided into tables to brainstorm potential messaging approaches. The top four issues agreed upon were: 1) knowledge of one's health leads to wellness, 2) people care about food ingredients so they should care about medicine ingredients, 3) patients are essential to medical research, and 4) people can learn about drugs from the independent EUPATI website. Some discussion followed on how to frame each message.
This document discusses the different roles patients can play in health technology assessment and decision making regarding new treatments. It identifies four types of patient voice: 1) as information providers who can provide key details about diseases and treatments to assessment bodies; 2) as decision makers who should be directly involved in decision making committees; 3) as policy makers who can help shape the processes by which patient voice is incorporated; and 4) as individuals making their own informed choices about treatments. The document argues that all four types of patient voice are important and should be involved in the assessment and decision making process.
The Innovative Medicines Initiative (IMI) is a public-private partnership between the European Union and the pharmaceutical industry that aims to boost pharmaceutical innovation in Europe. IMI supports pre-competitive research to accelerate the development of safer and more effective medicines through collaboration between stakeholders like industry, academia, patient organizations, and regulators. IMI is funded jointly by the EU and EFPIA members, with EU funds exclusively supporting public and nonprofit organizations and SMEs.
PPI Conference Galway - Dr Derick Mitchell - April 27th 2016ipposi
This document discusses the role of patients in science, industry, and research. It describes IPPOSI, a public-private partnership between patients, science, and industry in Ireland. IPPOSI members include patient advocacy groups and conduct various patient-led activities. The document also discusses EUPATI, a project to educate patients and the public about medicines research and development through training courses and an online toolbox. EUPATI aims to facilitate greater patient involvement in clinical research and regulatory processes.
How to communicate scientific and medical information to patients, advocates ...jangeissler
How to communicate scientific and medical information to patients, advocates and caregivers, presented by Jan Geissler at the European Medical Writer's Symposium (EMWA) on 12 May 2016
Research managers jan 14th, 2016 - ipposi presentationipposi
Irish Platform for Patient Organisations, Science & Industry - the importance of patient involvement in research, and patient training on medicines development and health research.
Patient Advocates in Cancer Research: European Patients’ Perspective - Jan ...patvocates
Patient Advocates in Cancer Research: European Patients’ Perspective, presented by Jan Geissler (Twitter @jangeissler) at ISOQOL 19th Annual Conference, Budapast, 26 Oct 2012
EUPATI’s framework on Informing the “health-interested” public about medicine...Nowgen
"EUPATI's framework on Informing the “health-interested” public objectively and comprehensively about medicines R&D", presented by Jan Geissler at the EUPATI 2014 Workshop in Warsaw
This document summarizes an organization called IPPOSI that trains patient experts on clinical research, health technology assessment, and eHealth. It discusses IPPOSI's members from science and industry backgrounds. It also describes EUPATI, a project that develops patient education on medicines research and development. EUPATI has trained over 100 patient experts and created educational materials available to over 12,000 patient advocates and 100,000 members of the public interested in health topics. The goal is to facilitate greater patient involvement in research by building competencies among patients.
EUPATI patient expert training course and its relevance for patient involvementEUPATI
The document discusses the EUPATI Patient Expert Training Course. It aims to educate and empower patients to be actively involved in all stages of medicine research and development from drug discovery through regulatory approval. The course includes 150-175 hours of online learning over 6 modules, along with two in-person meetings. It covers topics like clinical trials, ethics, regulations, health technology assessments, and more. The goal is to train independent and knowledgeable patient advocates who can partner with academics, industry, and regulators. Over 300 patients applied for the first class of 50-50 trainees, showing high interest. The course materials were developed by experts from different stakeholders and underwent extensive review.
Future Health Summit - Dr Derick Mitchell - May 26th 2016ipposi
This document discusses patient involvement in health research. It describes how patients can play key roles across various aspects of research including as public advisors, reviewers, co-researchers, and driving forces. It also outlines training programs for patients, such as those developed by IPPOSI and EUPATI, and how patients can be educated on clinical research, health technology assessment, and other areas. The goal is for patients to have objective knowledge about medical research and development processes to facilitate greater collaboration between patients and researchers.
Presentation in the framework of the International Conference "10th anniversary of the Spanish Network of Health Technology Assessment Agencies. Towads patient and public engagement in HTA" Zaragoza 27-28 April 2017
Presentation in the framework of the International Conference "10th anniversary of the Spanish Network of Health Technology Assessment Agencies. Towads patient and public engagement in HTA" Zaragoza 27-28 April 2017
This document summarizes the discussion from Break-Out Group 1 at the EUPATI 2015 Workshop regarding implementing EUPATI at the national level. Some key benefits of establishing a national EUPATI partner (ENP) include having a central point of contact for health policy questions, connecting diverse stakeholders, and facilitating multi-sectoral cooperation. National partners could include patient organizations, academics, regulatory authorities, healthcare professionals, and pharmaceutical companies. Strategic priorities for ENPs include disseminating EUPATI training and strengthening partnerships. Success would involve raising awareness, securing institutional support and sustainable funding, and becoming a go-to resource. ENPs should focus on building relationships, learning from more established programs, and leveraging partnerships
Introduction to the workshop and EUPATI updateEUPATI
The European Patients' Academy (EUPATI) project aims to educate patients and the public about medical research and development. It provides training to help patients become experts who can actively partner with researchers. The project is led by patients and involves various stakeholders. It has made progress in developing educational materials in multiple languages and establishing national networks. The first training course for patient experts recently began. EUPATI seeks to build understanding and empower patients to more actively engage in research.
The document discusses setting up a National Learning Team (NLT) to establish a European Patients' Academy (ENP) in their country to implement the EUPATI program before the end of 2015. Key points discussed include finding champions in patient organizations, academia, and industry; creating effective partnerships between these stakeholders; developing strategic links and growing networks; and emphasizing the benefits EUPATI can provide like training opportunities and access to resources to promote patient public involvement.
Reaching a public audience on medicines development: Anna ZawadaNowgen
"Reaching a public audience on medicines development", presented by Anna Zawada, Agency for Health Technology Assessment at EUPATI 2014 Workshop on 2 April 2014 in Warsaw
What were the success factors in this morning good practices examples, what a...Nowgen
"What were the success factors in this morning good practices examples", Results from Workgroup 2 presented by at EUPATI 2014 Workshop on 2 April 2014 in Warsaw
This document discusses patient involvement in science, industry, and research. It describes how the Irish Platform for Patient Organizations, Science and Industry (IPPOSI) brings together patient experts and organizations to encourage dialogue and influence decision making. IPPOSI members include patient experts in science and industry. The document also discusses the European Patients' Academy on Therapeutic Innovation (EUPATI) which provides training for patient experts through courses and educational materials. EUPATI aims to facilitate greater patient involvement in research and development.
A very important result from the EUPATI project was the development, broad consultation and final release of guidances on the best approach to interaction of patients with pharmaceutical industry-led medicines R&D, regulatory authorities, ethics committees and HTA agencies. This webinar focuses on the Patient Involvement in Industry-led R&D guidance document
How to raise interest in medicines development: Results from Workgroup 1Nowgen
The document reports on a workshop discussing strategies to raise public interest in medicines development. Participants were divided into tables to brainstorm potential messaging approaches. The top four issues agreed upon were: 1) knowledge of one's health leads to wellness, 2) people care about food ingredients so they should care about medicine ingredients, 3) patients are essential to medical research, and 4) people can learn about drugs from the independent EUPATI website. Some discussion followed on how to frame each message.
This document discusses the different roles patients can play in health technology assessment and decision making regarding new treatments. It identifies four types of patient voice: 1) as information providers who can provide key details about diseases and treatments to assessment bodies; 2) as decision makers who should be directly involved in decision making committees; 3) as policy makers who can help shape the processes by which patient voice is incorporated; and 4) as individuals making their own informed choices about treatments. The document argues that all four types of patient voice are important and should be involved in the assessment and decision making process.
The Innovative Medicines Initiative (IMI) is a public-private partnership between the European Union and the pharmaceutical industry that aims to boost pharmaceutical innovation in Europe. IMI supports pre-competitive research to accelerate the development of safer and more effective medicines through collaboration between stakeholders like industry, academia, patient organizations, and regulators. IMI is funded jointly by the EU and EFPIA members, with EU funds exclusively supporting public and nonprofit organizations and SMEs.
PPI Conference Galway - Dr Derick Mitchell - April 27th 2016ipposi
This document discusses the role of patients in science, industry, and research. It describes IPPOSI, a public-private partnership between patients, science, and industry in Ireland. IPPOSI members include patient advocacy groups and conduct various patient-led activities. The document also discusses EUPATI, a project to educate patients and the public about medicines research and development through training courses and an online toolbox. EUPATI aims to facilitate greater patient involvement in clinical research and regulatory processes.
How to communicate scientific and medical information to patients, advocates ...jangeissler
How to communicate scientific and medical information to patients, advocates and caregivers, presented by Jan Geissler at the European Medical Writer's Symposium (EMWA) on 12 May 2016
Research managers jan 14th, 2016 - ipposi presentationipposi
Irish Platform for Patient Organisations, Science & Industry - the importance of patient involvement in research, and patient training on medicines development and health research.
Patient Advocates in Cancer Research: European Patients’ Perspective - Jan ...patvocates
Patient Advocates in Cancer Research: European Patients’ Perspective, presented by Jan Geissler (Twitter @jangeissler) at ISOQOL 19th Annual Conference, Budapast, 26 Oct 2012
EUPATI’s framework on Informing the “health-interested” public about medicine...Nowgen
"EUPATI's framework on Informing the “health-interested” public objectively and comprehensively about medicines R&D", presented by Jan Geissler at the EUPATI 2014 Workshop in Warsaw
European Patients’ Academy on Therapeutic Innovation:Shifting paradigms in ...patvocates
"European Patients’ Academy on Therapeutic Innovation: Shifting paradigms in empowering patients on medical R&D": Presentation by Jan Geissler (Twitter @jangeissler) at the Belgian Association of Clinical Research Professionals (ACRP.be) meeting on 25 Oct 2012
Jan Geissler - How Patient (Advocates) discuss Clinical Research on the Internetpatvocates
"How Patient (Advocates) discuss Clinical Research on the Internet", presented by Jan Geissler (Twitter @jangeissler) at DIA Clinical Forum in The Hague on 9 Oct 2012.
The 9th Annual Patient Summit 2012 in London discussed the emergence of e-patients and their role in medical research and decision making. It highlighted patients' need for information to understand their disease and treatment options. The European Patients' Academy (EUPATI) was presented as a pan-European initiative to train patient advocates and provide educational resources to empower patients and facilitate their involvement in medical research.
Tripartite dimension of interaction of patients, regulators and industry (Jan...jangeissler
This document discusses the importance of interaction and partnership between patients, regulators, and industry in medicine research and development. It acknowledges that patient involvement enhances the quality of research, evidence, transparency, and mutual respect. The document outlines some challenges to interaction, including siloed thinking and lack of trust, and notes that EUPATI has helped improve collaboration but long-term sustainability is key. The objectives of the event are to share experiences of pilot projects involving these stakeholders and ensure their interaction is understood and trusted.
A snapshot of EUPATI: Why the educated patient is so vital to success in clin...jangeissler
A snapshot of EUPATI: Why the educated patient is so vital to success in clinical trials - Jan Geissler - EUPATI Director - presented at DIA EuroMeeting on 6 March 2013 in Amsterdam
Partnering with Patients: Designing, Participating in and Reporting Health Ou...patvocates
Partnering with Patients: Designing, Participating in and Reporting Health Outcomes - presented by Jan Geissler at ISPOR 19th ANNUAL CONGRESS in Dublin on 6 Nov 2013
The benefits of patient involvement in research and development (RE:ACT Congr...jangeissler
This document discusses the benefits of patient involvement in health research and development. It notes that innovation is transforming lives but more breakthroughs are still needed. Patients can provide unique perspectives to improve trial design and address unmet needs. However, public distrust and lack of knowledge limit patient participation in research. The document advocates for greater patient involvement at all stages of research, from setting priorities to disseminating results. It highlights the EUPATI initiative which aims to educate patients and the public about medicines research through training courses, educational tools, and national platforms. The goal is empowering patients as partners in research.
Presentation for EPEMED Webinar (11-27-12) FinalStig Albinus
This document discusses strategies for communicating the potential of personalized medicine to stakeholders in Europe. It begins by setting the context of the complexity of personalized medicine and the European healthcare landscape. It then examines stakeholders' current perceptions and initiatives related to personalized medicine. Several hypotheses are presented for how to advance adoption, including that social change is a major barrier, personalized medicine encompasses more than just genomics, and that a new health paradigm is needed. The document concludes by offering thought starters for communications strategies, such as humanizing genomics and demonstrating the new value model of personalized medicine. The desired future is for stakeholders like patients, physicians and policymakers to see personalized healthcare as empowering and improving outcomes while reducing costs.
A presentation delivered by IPPOSI CEO, Derick Mitchell at the University College Dublin PharmTox Society event on Clinical Trials in Ireland on March 6th, 2017
CHESS Connected Health training network - Derick Mitchell - August 2016ipposi
Patient-led organizations can play an important role in health research by providing the patient perspective. Training programs help develop "expert patients" who understand the research process and can actively partner with researchers. The EUPATI program has trained over 100 patient experts across Europe to collaborate in academic research, industry research, and regulatory committees. Their involvement aims to make research more relevant to patients' real needs and lives.
Geneva Pharma Forum on Pharmacovigilance: Partnering for
Patient Safety (Geneva, 20 November 2012), Jeremiah Mwangi, Director, Policy and External Affairs, IAPO
This document summarizes a presentation about patient involvement in research. It discusses:
1) IPPOSI, an organization that brings together patient groups, industry, and science to expedite development of innovative therapies and influence related policy in Ireland.
2) Current levels of clinical trial activity and the Irish public's attitudes toward clinical research, which show limited understanding but willingness to participate.
3) The need for more patient and researcher training to build understanding and partnership. The EUPATI program provides such training to develop "patient experts" who can meaningfully contribute to research.
4) Ireland's national platform involves several patient organizations to disseminate EUPATI training and build expertise among patients and advocates.
What do people think about medicines research and development? (Starling, EUP...Nowgen
The document summarizes findings from a large survey and qualitative research exploring public knowledge and attitudes towards medicines research and development (R&D) in six European countries. Key findings include:
- Low overall knowledge about medicines R&D across countries, ranging from 13-30% knowledgeable.
- Varied levels of trust in different R&D stakeholders between countries.
- Greatest interest in learning more about medicines safety, personalized medicine, and drug discovery.
- Preferred sources of information are doctors, websites, and television.
- Suggested focus areas for public engagement include the R&D process, clinical trials, regulations, and patient roles.
Similar to Education of patients (advocates) on R&D: European Patients’ Academy EUPATI (Jan Geissler) (20)
Don't just talk about patient centricity - put meaningful patient engagement ...jangeissler
"Don't just talk about patient centricity - put meaningful patient engagement into the design of your cancer research", presented by Jan Geissler at Meet2Win on 7/5/2021
CML: A tiger in the cage? A (European) perspective on CML disease managementjangeissler
CML: A tiger in the cage? A (European) perspective on CML disease management, presented by Jan Geissler, co-founder CML Advocates Network, at the 5th Friends of Max Leadership Summit in (virtual) India on 21 Feb 2021, Session "Beyond Borders"
Sicht der Patienten auf Real World Data, Register und Versorgungsdatenjangeissler
Sicht der Patienten auf Real World Data, Register und Versorgungsdaten. Präsentation von Jan Geissler beim FACHSYMPOSIUM ONKOLOGIE am 28.10.2020 im Rahmen der Sitzung "Daten aus der klinischen Versorgung - was leisten RWD, Register und versorgungsnahe klinische Studien in der Onkologie?"
Überblick der Aktivitäten von Leukämie-Online und CML Advocates Networkjangeissler
Präsentation von Jan Geissler und Cornelia Borowczak über die Aktivitäten von Leukämie-Online und CML Advocates Network, präsentiert beim Leukämie-Online-Patiententreffen am 22/23.9.2019 in Fulda
Umfrage zur Therapiefreien Remission (TFR) der CML-Patientengemeinschaftjangeissler
Präsentation der vorläufigen deutschen Ergebnisse der Umfrage der CML-Patientengemeinschaft zur den Erfahrungen, Ängsten und Erwartungen im Kontext der Therapiefreien Remission (TFR), präsentiert von Jan Geissler am 30.3.2019 beim Jahrestreffen der Deutschen CML-Allianz in Weimar
Bericht LeukaNET / leukaemie-online.de und CML Advocates Networkjangeissler
Bericht über die Aktivitäten von Leukaemie-Online.de / LeukaNET e.V. und CML Advocates Network, präsentiert auf dem Leukämie-Online-Treffen am 23/23. September 2018
How to get the most of the EHA congress as a CML patient advocatejangeissler
The European Hematology Association's (EHA) annual congress will start on 14 June 2018 in Stockholm. The co-founder of the CML Advocates Network and member of the EHA European Affairs Committee, Jan Geissler, on behalf of the EuroBloodNET ePAG, presents this webinar on how to get the most of EHA as a CML patient advocate.
Through the webinar you will be able to know more about topics as:
- Types of sessions at EHA and their relevance for a CML patient advocate
- How to set your priorities attending this huge congress.
- How to find and engage with key opinion leaders at the EHA Posters Sessions.
- More about EHA Abstracts: how to find them and how to read them.
European Patient Perspective on Access and Innovation with Multiplex Genomic ...jangeissler
European Patient Perspective on Access and Innovation with Multiplex Genomic Testing, presented by Jan Geissler at ASCO 2018 in Chicago, USA, on 3 June 2018
European Cancer Patient Advocacy: Introduction to the community, key stakehol...jangeissler
Overview of the European cancer patient advocacy community, key stakeholder interfaces and key initiatives and projects in evidence-based advocacy and capacity building. Presented by Jan Geissler, Patvocates, at European School of Oncology Masterclass, 23 Feb 2019, Lisbon, Portugal
Häufige Fragen von CML-Patienten und Welt-CML-Tag 2017jangeissler
"Häufige Fragen von CML-Patienten - und was am Welt-CML-Tag 2017 am 22.9.2017 los war", präsentiert von Jan Geissler im Symposium der Deutschen CML-Allianz beim Jahrestreffen der Deutschen Gesellschaft für Hämatologie und Onkologie (DGHO) am 29.9.2017 in Stuttgart
How to get the most of EHA as a patient advocatejangeissler
"How to get the most of EHA as a patient advocate", presented by Jan Geissler at the EHA / EuroBloodNet Capacity Building Meeting for Patient Advocates on 22 June 2017, Madrid
The Networked Patient Group: How technology changes the face of patient advocacyjangeissler
"The Networked Patient Group: How technology changes the face of patient advocacy", presented by Jan Geissler (@jangeissler) at European Patient Innovation Summit on 4 Oct 2016
Similarities and differences between Rare Cancers and Rare Diseasesjangeissler
While rare cancers (RCs) and rare diseases (RDs) face many similar challenges due to their rarity, there are also some key differences:
- RDs impact a larger number of different conditions (around 6000) compared to RCs (198 known types), and RDs are defined by prevalence while RCs by incidence.
- A majority of both RCs and RDs are life-threatening, but RDs more often affect children compared to RCs.
- Both communities struggle with delays in diagnosis, limited research funding, and a need for specialized treatment centers and clinical guidelines. However, RCs can take more advantage of research on common cancers, while RDs are more heterogeneous.
The role of patients and healthcare providers in translational medicinejangeissler
The role of patients and healthcare providers in translational medicine, presented by Jan Geissler at the European Commission's Personalized Medicine Conference 2016 on 1 June 2016 in Brussels
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...rightmanforbloodline
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Katzung, Verified Chapters 1 - 66, Complete Newest Version.
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Katzung, Verified Chapters 1 - 66, Complete Newest Version.
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Katzung, Verified Chapters 1 - 66, Complete Newest Version.
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Katzung, Verified Chapters 1 - 66, Complete Newest Version.
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Education of patients (advocates) on R&D: European Patients’ Academy EUPATI (Jan Geissler)
1. Jan Geissler – EUPATI Director
jan@patientsacademy.eu
Education of
patients (advocates) on R&D:
European Patients’ Academy
on Therapeutic Innovation
The project is receiving support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115334, resources of which are composed
of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies.
3. Medical landscape is changing
at a fast pace
Innovation transforms the lives of
patients with serious, lifelong conditions:
Molecular targets/pathways
Genome sequencing,
Translational research
Personalized medicine
• Small trial populations
• Biomarkers, companion diagnostics
Need for post-marketing data
Health Technology Assessment,
QoL, endpoints, comparators
BUT long term pressure on health budgets
– here to stay
Window of
opportunity
trial design
relationship
between
researchers,
regulators,
industry,
patients
3
4. Patients – as key partners of researchers
More needs to be done: rare cancers will never be a priority unless
the patients make it one. Patients themselves must therefore
play a larger role in driving forward the search for therapies.
They are able to see connections that have eluded scientists.
“ „
5. Unique examples of patient involvement in
R&D and regulatory affairs already today
Patients' and Consumers' Working Party
6. Patient advocates’ key role in building
new environment for R&D
Patient organisations have unique insights
into „real life“ and „real needs“ of patients:
• Gaps research priorities
• Clinical trial design
• Quality of Life, Side effects
• Real-world access to therapies
• „Value“
• Patient-centered research policy
PatientPartner FP7 Project (2010),
www.patientpartner-europe.eu
Research subject
Info provider
Advisor
Reviewer
Co-researcher
Driving force
7. Public
Research Ethics
Committees
Competent
authorities
Policy makers
/Research Policy
HTA agencies
& committees
Research subject
Info provider
Advisor
Reviewer
Co-researcher
Driving force
Clinical
Research
Patients have a key role in all aspects of
health-related research
Trial protocol design,
informed consent, ethical
review, marketing
authorization, value
assessment, health policy
8. European Patients’ Academy: Paradigm shift
in empowering patients on medicines R&D
Launched Feb ’12, runs for 5 years,
30 consortium members,
Funded by IMI JU
will develop and disseminate
objective, credible,
correct and up-to-date public
knowledge about medicines
R&D
will build competencies
& expert capacity among patients & public
will facilitate patient involvement in R&D to collaborate in academic
research, industry research, authorities and ethics committees
9. Project led by 4 key pan-European
patient associations
◦ EUPATI Project Coordination
◦ >50 umbrella patient
organisations.
◦ Linking national and regional
patient alliances
◦ >600 rare disease
organisations in
>45 countries
◦ >100 members in over 30
countries
10. Areas covered by the
European Patients’ Academy
1. Discovery of Medicines & Planning of Medicines Development
2. Non-Clinical Testing and Pharmaceutical Development
3. Exploratory and Confirmatory Clinical Development
4. Clinical Trials
5. Regulatory Affairs, Medicinal product Safety, Pharmacovigilance
and Pharmaco-epidemiology
6. Health Technology Assessment and the
economics
…and NOT:
develop indication-
or therapy-specific
information!
11. EUPATI Internet Library
EUPATI Educational Toolbox
EUPATI Training Programme
To bring this to life, EUPATI develops
education targeted at different levels
100
“expert”
patient
advocates
12.000
patient
advocates
100.000
individuals
AT
BE
CH
DE
ES
FR
IT
IE
LU
MT
PL
UK
12. EUPATI Blended Learning
“Expert Patient” Training Course
In-depth course for patient advocates to be able to contribute to
medicines R&D in academic groups, industry, competent authorities
(EMA & national), research policy etc.
Course recruitment has opened on 6 March 2014,
closing date 20 April 2014, start of course Sept 2014
Apply at www.patientsacademy.eu/apply
e-Learning
EUPATI Training Programme
9/2014 – 9/2015
Application
Phase
3-4/2014
e-Learning f2f e-Learning f2f
Certificate
Internet Library
Toolbox
Courses
13. Next steps
EUPATI Public Workshop 2014
“Reaching a Public Audience on
Medicines Development”, 2 April 2014,
Warsaw
Start of EUPATI Course
apply until 20 April 2014!
13
14. To address unmet needs
and make research more patient-centric,
(more) patient advocates need
to be involved as partners.
EUPATI helps
to make that happen.